BIOVIE INC.
BIVIDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
NE3107 Phase 2 Est. Readout
Estimated primary completion for NE3107 trial (NCT06847191) in Long COVID. Topline data typically follows completion by weeks to months.
SourceHow BIVI's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NE3107 | Phase 3 | Parkinsons Disease (PD) | - | - |
Terlipressin acetate continuous infusion | Phase 2 | Cirrhosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BIOVIE INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in BIOVIE INC.'s (BIVI) pipeline across Phase 3, Phase 2. Its lead program is NE3107 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BIOVIE INC.'s next FDA catalyst?→
BIOVIE INC.'s (BIVI) next tracked catalyst is a Phase 2 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIVI biotech catalysts?→
Add BIVI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BIOVIE INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.